Lipo-Hepin en es it fr

Lipo-Hepin Brand names, Lipo-Hepin Analogs

Lipo-Hepin Brand Names Mixture

  • No information avaliable

Lipo-Hepin Chemical_Formula


Lipo-Hepin RX_link

Lipo-Hepin fda sheet

Lipo-Hepin FDA

Lipo-Hepin msds (material safety sheet)

Lipo-Hepin MSDS

Lipo-Hepin Synthesis Reference

No information avaliable

Lipo-Hepin Molecular Weight

12000-15000 g/mol

Lipo-Hepin Melting Point

No information avaliable

Lipo-Hepin H2O Solubility


Lipo-Hepin State


Lipo-Hepin LogP

No information avaliable

Lipo-Hepin Dosage Forms

Solution for subcutaneous injection; Intravenous injection; Intravenous infusion

Lipo-Hepin Indication

For anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension, for prevention of post-operative deep venous thrombosis and pulmonary embolism and for the prevention of clotting in arterial and cardiac surgery.

Lipo-Hepin Pharmacology

Heparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Heparin is a well known and commonly used anticoagulant which has antithrombotic properties. Heparin is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Heparin acts at multiple sites in the normal coagulation system. Small amounts of Heparin in combination with antithrombin III (Heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.

Lipo-Hepin Absorption

Some oral absorption but lack of anticoagulant effect. Rapidly taken up by endothelial cells with remainder bound to plasma proteins.

Lipo-Hepin side effects and Toxicity

Heparin sodium - Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors

Lipo-Hepin Patient Information

No information avaliable

Lipo-Hepin Organisms Affected

Humans and other mammals